Indivior Pharmaceuticals, Inc. (INDV)

Over the past six months, Indivior's stock price has been influenced by several events. The company completed its redomiciliation to the U.S. on January 26, 2026. On February 26, 2026, Indivior reported strong fourth-quarter and full-year 2025 financial results, but the market reacted cautiously due to concerns regarding the execution risk of the company's "Accelerate" growth plan. Weak 2026 total revenue guidance, announced in January 2026 and reaffirmed in February 2026, projected a decline in total net revenue. In March 2026, Indivior announced and priced an upsized $450.0 million convertible senior notes offering. On March 31, 2026, Indivior announced findings from a new real-world evidence study highlighting the potential for SUBLOCADE to reduce staffing burdens and healthcare utilization in correctional facilities. Indivior is scheduled to report its first-quarter 2026 financial results on April 30, 2026. Over the past 12 months, Indivior's stock price has risen significantly, but there has been some recent volatility and a decrease in price over the last few weeks.

The provided information does not explicitly detail any significant demand seasonality for Indivior Pharmaceuticals, Inc.'s products. Demand for its products is likely to be relatively stable throughout the year rather than exhibiting strong seasonal fluctuations.

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for opioid use disorder (OUD) and other serious mental illnesses. The company's core business revolves around buprenorphine-based prescription drugs for opioid dependence, with major products including SUBLOCADE, SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet. Indivior also offers OPVEE for opioid overdose reversal and PERSERIS for schizophrenia, and is actively developing new product candidates like INDV-2000 and INDV-6001 for OUD.

Indivior Pharmaceuticals, Inc. is headquartered in North Chesterfield, Virginia, United States. The company has a global presence with offices and research centers in Virginia, North Carolina, and the United Kingdom. Its products are available in 37 countries, with significant operations in the United States, which generates the vast majority of its revenue. Other international locations include Canada, the UK, Germany, Ireland, Israel, Italy, France, the Nordics (Sweden), and Australia.

While no specific negative reputation events within the past year were explicitly detailed, Indivior was indicted in 2019 over claims of false marketing regarding the safety of its drug Suboxone. More recently, Indivior's public communications emphasize its commitment to transforming the lives of people affected by OUD through science, compassion, and advocacy.

Indivior Pharmaceuticals, Inc. has significant institutional ownership. Major institutional shareholders include BlackRock, Inc., Oaktree Capital Management Lp, Fuller & Thaler Asset Management, Inc., Vanguard Group Inc, Two Seas Capital LP, State Street Corp, Morgan Stanley, Deerfield Management Company, L.p. (series C), and Goldman Sachs Group Inc. Institutional shareholders collectively hold approximately 97.13% of the company's shares, while insiders own about 0.74% and retail investors hold around 2.13%.